Although we know that KRAS tumor mutations limit benefit from Erbitux, about six out of ten colorectal cancer patients have normal or wild type KRAS. Yet Erbitux doesn’t work for many of them either.
There may be a simple way to predict early in treatment whether Erbitux is going to help to not.
Significantly more patients whose blood levels of magnesium dropped more than 50 percent after their first treatment with irinotecan and Erbitux had their tumors shrink. It also took longer before their cancer got worse, and they lived longer. Read the rest of this entry »